ALTERNATIVE APPROACHES TO THERAPY FOR ENDOMETRIAL HYPERPLASTIC PROCESSES IN PERIMENOPAUSE
https://doi.org/10.17650/1994-4098-2008-0-4-43-45
Abstract
The study included 68 perimenopausal patients. Group 1 comprised 34 women with endometrial hyperplastic processes (a study group); Group 2 consisted of 34 women without endometrial pathology (a control group). The authors conducted physical examination, small pelvic ultrasonography, hysteroscopy with endometrial biopsy, measured the urinary estrogen metabolites 2-OHE1/16α-OHE1 ratio by enzyme immunoassay, and determined the levels of total estrogens. Statistically significantly increased 16α-OHE1 concentrations, a low 2-OHE1/16α-OHE1 ratio, and elevated levels of total estrogens were found in Group 1 women. No recurrent endometrial hyper- plasia, as well as lower levels of total estrogens and 16α-OHE1 and a higher 2-OHE1/16α-OHE1 ratio were observed after using indi- nol in a dose of 300 mg/day for 3 months in 20 patients from the study group.
About the Authors
N. V. Artymuk
Department Two of Obstetrics and Gynecology, Kemerovo State Medical Academy
Russian Federation
Russian Federation
Ye. L. Kharenkova
Department Two of Obstetrics and Gynecology, Kemerovo State Medical Academy
Russian Federation
Russian Federation
A. G. Trishkin
Department Two of Obstetrics and Gynecology, Kemerovo State Medical Academy
Russian Federation
Russian Federation
References
1. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивных органов (этиология и патогенез). М.: Миракс Фарма, 2007.
2. Гуляева Л.Ф., Красильников С.Э. Молекулярно-генетические аспекты патогенеза рака эндометрия. Сиб онкол журн 2007;Прил. 1:26—31.
3. Медицина климактерия. Под ред. В.П. Сметник. М., 2006.
4. Bochkareva N.V., Kondakova I.V., Kolomiets L.A. Endometrial cancer and enzymes of estrogen metabolic pathway: correlation with clinical and histopathologi- cal parameters. 5th Biennial International meeting of the FGOG «Endocrine treat- ment & prevention of breast and gynaeco- logical cancers». Brussels, 2006.
5. Берштейн Л.М. Согласованные и спорные аспекты патогенеза и гормонотерапии рака эндометрия: точка зрения эндокринолога. Сиб онкол журн 2007;Прил. 1:124—5.
6. Agorastos T., Vaitsi V., Paschopoulos M. et al. Рrologed use of gonadotropin-releasing hormone agoinist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas 2004;48:125—32.
7. Brun J.L., Descat E., Boubli B., Dallay D. Endometrial hyperplasia: a review. J Gynecol Obstet Biol Reprod (Paris) 2006;35:542—60.
8. Денисова Н.С. Значение агониста ГнРГ бусерелина-депо в терапии больных гиперпластическими процессами эндометрия в перименопаузальном периоде. Журн Рос общ акуш гинекол 2006;(2):32—3.
9. Lai C.H., Huang D.J. The role of hor- mones for the treatment of endometrial hyperplasia and endometrial carcinoma. Curr Opin Obstet Gynecol 2006;18:29—34.
10. Sturdee D. Management of endometrial hyperplasia. Gynecol Endocrinol 2008;24(1):52—3.
11. Zullo F. Endometrial ablation: new tools. Gynecol Endocrinol 2008;24(1):24—5.
12. Киселев В.И., Муйжнек Е.Л. Роль метаболитов эстрогенов в канцерогенезе репродуктивных органов. Материалы VІІ Российского форума «Мать и дитя». М., 2005.
13. Киселев В.И., Ляшенко А.А. Индинол — регулятор пролиферативных процессов в органах репродуктивной системы. М., 2005.
Review
For citations:
Artymuk N.V., Kharenkova Ye.L., Trishkin A.G. ALTERNATIVE APPROACHES TO THERAPY FOR ENDOMETRIAL HYPERPLASTIC PROCESSES IN PERIMENOPAUSE. Tumors of female reproductive system. 2008;(4):43-45. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-4-43-45
Views:
610
Email this article 